Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral T-cell Lymphoma (PTCL) Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

NCT01994382
View directory record Official record
Conditions
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions
Cerdulatinib, Rituximab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
23
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

NCT00274651
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Stanford, California • New Haven, Connecticut • Lenexa, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions
romidepsin, lenalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584
View directory record Official record
Conditions
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
Interventions
KT-333
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Orange, California • Louisville, Kentucky • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471
View directory record Official record
Conditions
T-cell NHL (PTCL or CTCL)
Interventions
KK2223
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Duarte, California • Orange, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 1 Interventional

A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

NCT03952078
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
CPI-818
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Ann Arbor, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Interventions
RP6530
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

NCT02594267
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma (PTCL)
Interventions
Pralatrexate Injection
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

NCT00787527
View directory record Official record
Conditions
Lymphoma
Interventions
Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 1 Interventional

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791
View directory record Official record
Conditions
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage IB Mycosis Fungoides AJCC v7, Stage II Mycosis Fungoides AJCC v7, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides AJCC v7, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides AJCC v7
Interventions
Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

NCT01841021
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Brentuximab vedotin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806
View directory record Official record
Conditions
Hodgkin Disease, Peripheral T Cell Lymphoma
Interventions
brentuximab vedotin, bendamustine, dacarbazine, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925
View directory record Official record
Conditions
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

NCT01142674
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Not listed
Lead sponsor
Associazione Angela Serra per la ricerca sul cancro
Other
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282
View directory record Official record
Conditions
Relapsed or Refractory T Cell Lymphoma
Interventions
ONO-4685
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

NCT02978235
View directory record Official record
Conditions
Multiple Myeloma, NonHodgkin Lymphoma
Interventions
TAS4464
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Bethesda, Maryland • Boston, Massachusetts • Farmington Hills, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Suspended Phase 1Phase 2 Interventional

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

NCT05138458
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
Interventions
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Biological · Other
Lead sponsor
Myeloid Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Duarte, California • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Results available

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

NCT02663518
View directory record Official record
Conditions
Hematologic Malignancies, Solid Tumor
Interventions
PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
47
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

NCT00888927
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
KW-0761
Biological
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

NCT02689453
View directory record Official record
Conditions
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T Cell Lymphoma (CTCL), T-Cell Prolymphocytic Leukemia
Interventions
IL-15 plus, alemtuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05403450
View directory record Official record
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma
Interventions
Tolinapant, Decitabine + Cedazuridine
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

NCT05239910
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Tenalisib
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 17, 2026, 5:15 AM EDT